RAPID-CRISPR: highly sensitive diagnostic assay for detection of PML::RARA isoforms in acute promyelocytic leukemia

•RAPID-CRISPR assay provides swift diagnosis of APL that facilitates timely therapeutic intervention minimizing the risk of early mortality.•Designed for resource-limited settings, this assay features an easy-to-read format with 100% sensitivity and 100% specificity. [Display omitted] Acute promyelocytic leukemia (APL), distinguished by the presence of PML::RARA fusion transcript, is a medical emergency because of its high early death rate, which is preventable when diagnosed early. Current diagnostic methods are precise and reliable but are time intensive, require sophisticated instruments, and analytical expertise. This study has redefined APL identification by CRISPR system (RAPID-CRISPR) to rapidly (